The first-generation tests targeting a cryptic plasmid for the C. trachomatis diagnostics showed a relatively high sensitivity; however their usefulness has recently been compromised by the discovery of C. trachomatis strains lacking the target DNA segment (e.g. the "Swedish" variant) or variants bearing no plasmid at all and thus escaping the diagnostics. Aim. We propose the addition of a C. trachomatis chromosome gene as a PCR target to back up plasmidbased assays and enhance the overall efficiency of diagnostics. Methods. Two multiplexed PCRs were set up to target C. trachomatis cryptic plasmid and the 16s rRNA gene. The 16s rRNA primers produce PCR signal from a range of Chlamydia species whereas the introduction of a Taqman probe (essential for the real-time PCR) scales the assay down to C. trachomatis. At the same time, our plasmid PCR is specific to C. trachomatis exclusively. Results. The sensitivity of plasmid and 16s rRNA PCRs ranged between one to ten genome-equivalents per reaction (geq/rxn) whereas the efficiency was always ~100%. Multiplexing did not reduce the analytical sensitivity. Addition of DNA prepared from clinical specimens to the reaction mix did not affect PCR with pure C. trachomatis DNA further demonstrating the robustness of this system. The kinetics of the two reactions was compared in 49 DNA samples prepared from C. trachomatis-positive swabs. In 45, reactions showed a good correlation in the threshold cycle of amplification Cq, the main analytical parameter of real-time PCR. Conclusions. The simultaneous detection of chromosomal and plasmid targets in the multiplex PCR offers a high sensitivity and is particularly advantageous for specimens where the plasmid might be lost due to DNA degradation or counter-selection after treatment. The dual PCR strategy constitute the core of a diagnostic test for both in-house and commercial use.
Introduction
Chlamydia is a causative agent of a series of urogenital, respiratory and ocular disorders in humans and animals [1] . Although in most cases infections are asymptomatic, severe outcomes occur when the pathogenassociated damage is aggravated by an in-adequate immune response [2, 3] . C. trachomatis is the most clinically important and hence best-stu died representative of the phylum. This is a sexually transmitted obligate intracellular gram-negative bacterium. If not treated it can cause pelvic inflammatory disease, infertility, ectopic pregnancy, urethritis, infant pneumonia and blindness [3] . Therapy of C.trachomatis infection relies mainly on broad-spectrum antibiotics such as azithromycin and doxycycline, and no pathogen-specific treatment has been implemented as yet [4] .
The diagnostics of Chlamydia infection in humans and animals makes a wide use of PCR [4] . For C. trachomatis, the cryptic plasmid which is somehow linked with infectivity [5] has long been the primary target in PCR tests [6] . The plasmid is present in up to 10 copies per cell [7] . However, a variant was discovered in Sweden where the plasmid had a deletion encompassing the target region used in diagnostic kits of that time [8, 9] . It was suggested that the deletion had been rapidly selected due to the diagnostic advantage it provided to the microorganism oppressed by screening programs. Moreover, plasmid-less variants have also been reported [10, 11] . Therefore, other PCR targets have been suggested: momp1 (major outer membrane protein) [12] , omcB (outer membrane complex B protein) [13] , gyrase A [14] , 16s rRNA [10, 15] , 23s rRNA
Here we present a set of PCRs targeting the C. trachomatis cryptic plasmid, 16s rRNA gene and a synthetic plasmid as an internal control. These reactions could constitute the basis of an in-house or affordable commercial diagnostic kit. They are highly sensitive, robust and amenable for multiplexing. The dual-target strategy appears to be particularly useful for problematic specimens in which a partial loss of DNA due to degradation or deletion might be an issue. The threshold cycle of amplification Cq was registered as a point at which the amplification curve reached the intensity of fluorescence of 50 relative units. The efficiency of PCR was calculated using the formula:
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where E -efficiency, "slope" -the slope of the trend line of the Cq dependence on the log 10 of concentration of reference C. trachomatis DNA (Fig. 3B and C) .
Results
Primers, probes and target regions
Our principle idea was to supplement a plasmidbased reaction with another one targeting some genomic fragment. Thus the test would be insured from plasmid-instability issues while keeping an elevated level of the analytical sensitivity suggestively provided by several copies of plasmid. The 16s rRNA gene was chosen as the target genomic fragment due to a unique pattern of conservative and hypervariable motives [15] . There are two copies of this gene in C. trachomatis separated by about 20 kb (Fig. 1A ). Primers were designed to detect a range of Chlamydia species thus reserving a possibility of detecting the Chlamydia genus without specification which might be in demand in certain clinical and veterinary situations. At the same time, the hexachlorofluorescein (HEX)-labeled Taqman probe is C. trachomatis -specific: mismatches to the corresponding sequence of other species are sufficient to abrogate the detection in real-time PCR (Fig. 1A) .
The cryptic plasmid is detected by a pair of primers targeting the predicted coding sequence CDS3 (Fig. 1B) . Note that the targeted region lies outside of the 377-bp Swedish deletion. The function of CDS3 is yet unknown; interaction with other plasmid-born CDSs and chromosomal genes has been suggested [16] . The probe is labeled by 6-carboxyfluorescein (FAM) thus enabling multiplexing with the 16s rRNA PCR detected by HEX fluorescence.
If PCR reaction is aimed to be used as a diagnostic test it must be accompanied by an internal control reaction. A positive PCR signal from the internal control would indicate that PCR conditions were correct and the compo- shown by arrows. This panel is adopted from a diagram published earlier [9] . A kind permission of the author, Dr. Helena Seth-Smith, was granted.
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nents of the PCR machinery worked properly. In this case, a negative result of the target reaction could surely be interpreted as the absence of the pathogen DNA in the sample (or its presence below the sensitivity threshold), not as a result of PCR failure. We designed a third reaction templated by the pUC18 plasmid bearing an insert in the multiple cloning site (see Materials and Methods). This plasmid should be added to the reaction mix along with sample DNA. The forward primer anneals to the insert; the reverse primer anneals to the bLactamase gene which is a part of the original pUC18 backbone sequence. It was crucial to position one of the primers to a synthetically introduced insert. If we otherwise placed both primers to the backbone an undesirable background PCR signal would be produced from the homologous expression vectors usually present in recombinant Taq polymerase stocks as an admixture. Note that such vectors are inevitably carried over to the PCR mix and produce a detectable amplicon [17] after about 30 cycles (data not shown). The Taqman probe for this reaction carries the cyanine 5 (Cy5) dye whose maximum of fluorescence emission (670 nm) lies away from that of FAM (517 nm) and HEX (556 nm) labeling the 16s rRNA and cryptic plasmid reactions, respectively. PCR with 16s rRNA primers amplified a distinct 156-bp product from purified DNA of C. trachomatis (Fig. 2, lanes 2 and 3) and some other Chlamydia species (Fig. 2, lanes 8-14) . No 156-bp product was detected in DNA from Escherichia coli, Bacillus cereus, Listeria monocytogenes, Mycoplasma arginini (Fig. 2,  lanes 4-7) , Bacillus thermocatenulatus, Campylobacter pylori, Lactobacillus rhamnosus (data not shown). Non-specific products of a higher molecular weight seen in PCR from some non-Chlamydia species have no diagnostic value. Cryptic plasmid, appearing as a 266-bp product, was detected only in PCR from C. trachomatis DNA (Fig. 2, lane 3) .
PCR from reference C. trachomatis DNA
A triplex PCR consisting of reactions targeting the 16s rRNA gene and cryptic plasmid of reference C. trachomatis along with internal control produced a typical sigmoid curve (Fig. 3A) and distinct electrophoretic band (Fig. 3B) for each of the three reactions. Note that the internal control PCR (smooth grey curves) does not appear to be inhibited by the two diagnostic reactions (symbol-marked curves) even at elevated concentrations of template DNA. The individual analytical sensitivity of the diagnostic reactions in triplex was assayed on ten-fold dilutions of pure C. trachomatis DNA spanning four orders of magnitude ( Fig. 3C and D) . Reproducible sigmoid curves were observed for both reactions in the presence of as low as five genome-equivalents per reaction mix (which is equal to the value of 0.7 in the logarithmic form). We monitored Cq, a PCR cycle at which the kinetics passes from the lag to exponential stage. The Cq is considered as the main quantitative parameter of realtime PCR. In our assays, a ten-fold increment in the template concentration translated in the Cq decrease of about 3.3 cycles throughout the entire concentration range. Consequently, the PCR efficiency was close to one (100 %) indicating that (i) no loss of sensitivity happens upon dilution of the sample, (ii) no inhibition is caused by higher concentrations of template DNA.
It is often speculated that multiplexing might weaken PCR because of unpredictable oligonucleotide heteroduplexes and/or exhausting PCR components. We compared the performance of our diagnostic reactions in the monoplex versus triplex format (Fig. 4 , smooth and symbol-marked curves, respectively).
No significant change in Cq and overall shape of curves has been observed at both high (4.7 log 10 geq/rxn) and low (0.7 log 10 geq/rxn) concentrations of pure C. trachomatis DNA. Thus we could dispel concern of a sensitivity loss due to multiplexing.
Clinical samples
Up to this point, the proposed strategy of dualtarget PCR has been tested only on pure reference DNA. Skepticism might hold that DNA from real clinical specimens could perform weaker in terms of the sensitivity and robustness. In view of this, we examined our reactions in triplex on reference C. trachomatis DNA with and without DNA isolated from C. trachomatis-negative specimens (Fig. 5 , symbol-marked and smooth curve, respectively). Plasmid and 16s rRNA PCRs (Fig. 5A and B, respectively) produced a detectable fluorescent signal throughout a range of template DNA concentrations spanning four orders of magnitude. We did not observe any significant difference between real-time PCR curves registered in the presence or absence of clinical sample DNA. Thus the proposed PCR reactions are robust enough for the detection of C. trachomatis DNA in clinical specimens.
Next we compared the performance of 16s rRNA and cryptic plasmid reactions on real C. trachomatis -positive samples (deemed such by commercial PCR kits; Fig. 6 ). We carried out triplex PCR (with the addition of internal control) and plotted the results as dots on the plane formed by two Cq values. In such representation, the results lie along the diagonal line indicating that the two reactions sense the variation of the amount of C. trachomatis DNA in a similar manner. There were 45 such Fig. 4 . A negligible effect of multiplexing on the PCRs for C. trachomatis. Pure C. trachomatis DNA was used to give the indicated number of log 10 geq/rxn. PCR was done either in triplex with primers to 16s rRNA (green triangles) + cryptic plasmid (blue circles) + internal control (not shown) or monoplex with primers to 16s rRNA or cryptic plasmid (green and blue curves, respectively, without any symbol). samples out of total 49. In four outliers, one of the two reactions failed or poorly performed as judged by a higher Cq: one with plasmid and three with 16s rRNA. These results were essentially confirmed by re-analyzing the backup stocks starting from DNA (data not shown). Overall, the two reactions were equally efficient on clinical specimens: the mean Cq was 28.2 and 28.3 for cryptic plasmid and 16s rRNA, respectively. Therefore, 16s rRNA and cryptic plasmid PCRs can complement each other in problematic cases thereby minimizing the chance of a false-negative result.
Discussion
About 90 million cases of C. trachomatis infection are diagnosed worldwide and the incidence has grown within the last decade [18] . A large proportion of infections proceeds asympthomatic and undetected, yet pelvic inflammatory disease could develop with a various probability and cause infertility in up to 18 % of cases [19] . Despite screening programs have been designed and promoted recently [20] , many communities and regions still have a limited access to high-quality C. trachomatis diagnostics. The advent of molecular techniques, such as PCR, holds a great promise to improve the management of infectious diseases at the population level in general.
Here we suggested that targeting two loci could greatly improve C. trachomatis PCR diagnostics. We chose the 16s rRNA gene as the chromosomal target to supplement plasmid-born PCR. First, it is present in at least two copies (Fig. 1A) thus backing up the test if one of the copies picks up a mutation affecting the primer -template interaction. Second, we wanted to reserve an option to detect nontrachomatis Chlamydiaceae which would expand the use of 16s rRNA reaction in clinical and veterinary diagnostics. The 16s RNA gene offers enough conserved motives for designing primers to 16s rRNA sequence from a range of Chlamydia species (Fig. 2) . At the same time, our Taqman probe (Fig. 1A) was sufficiently restrictive narrowing down the range to C. trachomatis (Fig. 3 and data not shown) .
The sensitivity and efficiency were similar for 16s rRNA and plasmid PCR, on both pure DNA (Fig. 3) and clinical samples (Fig. 6) . The reactions were performed well in the multiplex format (Figs. 3 and 4) . Thus the system does not appear to be affected by a reciprocal inhibiting effect of the reactions and exhaust of active components towards the end of PCR. Furthermore, the reactions were not perturbed by inhibitors potentially carried through the DNA isolation step (Fig. 5 and data not shown). Thus this PCR set could be combined with various DNA isolation kits and integrated into an existing laboratory workflow. Despite a high analytical sensitivity, the clinical sensitivity of a test based on the proposed reactions remains to be determined. This should be done on a panel of reference clinical samples prepared under the same conditions and deemed C. trachomatis-positive by a "golden standard" test.
For the quantification of C. trachomatis, 16s rRNA PCR appears more advantageous because the plasmid copy number is a variable parameter per se. Our results show that 16s rRNA, as a PCR target, is not worse than plasmid used traditionally. However, it would be premature to refuse from targeting the plasmid which is believed to be somehow associated with virulence [5] . It is plausible that the diagnostics of the future will be focused more on highly virulent stages and variants in order to avoid unnecessary therapeutic measures.
In rare samples, one of the two reactions failed (Fig. 6 ) which could be caused by (i) partial DNA degradation, (ii) sequence variation in primer target sites, (iii) infection eradication. In general, since many aspects of C. trachomatis biology and pathogenesis still remain unclear we suggest that a PCR diagnostic kit must be somewhat redundant. The use of two reactions, able to back-up each other on problematic samples, appears to be advantageous for the test's reliability.
Conclusions
The dual-target strategy for PCR detection of C. trachomatis presented here benefits from the simultaneous targeting the cryptic plasmid and 16s rRNA gene. Such a strategy offers a high sensitivity and reproducibility, performs well upon multiplexing, and ensures an efficient C. trachomatis detection in samples where one of the targets is lost. Adoption of these reactions could be a launching point in the development of a quantitative kit for both in-house use and commercial production.
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